Download the Whitepaper
Repurposing Therapies Used in Native Immune Mediated Renal Diseases to Treat Allograft Rejection
As discussions at ERA 2026 highlighted the growing momentum around precision therapies in nephrology and transplantation, an important question remains: can advances in native immune-mediated kidney diseases help address persistent unmet needs in allograft rejection?
In the following whitepaper, developed in collaboration with Dr. Amit Govil of University of Cincinnati, Medpace renal experts examine the shared mechanisms between IgA nephropathy (IgAN) and antibody-mediated rejection (ABMR), and explore how emerging therapies may be repurposed to improve outcomes in kidney transplantation.
Your Next Breakthrough Starts Here
Leading Transplantation CRO
Medpace brings deep expertise and global execution to transplantation clinical development, spanning solid organ (e.g., renal, hepatic) and hematopoietic stem cell transplantation. Our multidisciplinary teams — including in-house nephrologists, infectious disease specialists, and immunologists — partner with Sponsors to accelerate programs that aim to improve graft survival, minimize rejection, and advance post-transplant outcomes.